Fibrates News and Research

RSS
EAS/ESC develops new dyslipidaemias guidelines

EAS/ESC develops new dyslipidaemias guidelines

Fibrate drugs may not prevent heart attacks in diabetes patients with elevated cholesterol

Fibrate drugs may not prevent heart attacks in diabetes patients with elevated cholesterol

EAS, ESC develop new European guidelines to manage dyslipidaemias

EAS, ESC develop new European guidelines to manage dyslipidaemias

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Abbott appreciates FDA Advisory Committee recommendations to retain Trilipix indication for mixed dyslipidemia

Abbott appreciates FDA Advisory Committee recommendations to retain Trilipix indication for mixed dyslipidemia

TZDs might serve as new agents for addiction treatment

TZDs might serve as new agents for addiction treatment

Use of fibrates for high lipid levels increases despite uncertain improvement in clinical outcomes

Use of fibrates for high lipid levels increases despite uncertain improvement in clinical outcomes

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

VYTORIN reduces major vascular events in patients with chronic kidney disease

VYTORIN reduces major vascular events in patients with chronic kidney disease

Metabolon receives patent for biomarkers to determine PPAR-affecting drugs

Metabolon receives patent for biomarkers to determine PPAR-affecting drugs

Essentialis receives patent for active component in DCCR product

Essentialis receives patent for active component in DCCR product

Study identifies treatment strategies that can slow progression of eye disease associated with diabetes

Study identifies treatment strategies that can slow progression of eye disease associated with diabetes

Data from ACCORD Lipid study: Abbott issues statement

Data from ACCORD Lipid study: Abbott issues statement

Combination therapy does not reduce cardiovascular risk in type 2 diabetes patients

Combination therapy does not reduce cardiovascular risk in type 2 diabetes patients

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee

AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee

AstraZeneca's CRESTOR approved for treating pediatric patients with HeFH

AstraZeneca's CRESTOR approved for treating pediatric patients with HeFH

Compounds that bock nutrient-sensing receptor may impact obesity and diabetic conditions

Compounds that bock nutrient-sensing receptor may impact obesity and diabetic conditions

Common food additive lecithin may help control blood lipids and reduce disease risk

Common food additive lecithin may help control blood lipids and reduce disease risk

90 per cent of the world's population won't have access to antivirals in pandemic - generic drugs may help though

90 per cent of the world's population won't have access to antivirals in pandemic - generic drugs may help though